BUFFALO, NY -- (MARKET WIRE) -- 04/11/08 -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced today that Daniel Mallin, Ph.D. and Stephen Brozak of WBB Securities, LLC have updated coverage on the Company.

The WBB Securities report, dated April 11, 2008, assigned a Strong Buy rating to the Company, and reiterated a 12-month target price of $13.00. The report's introduction stated, "In the past eight days, three significant events have taken place that validate CBLI's science, underscore the company's viability and improve the company's outlook." The report then summarized these events.

Interested parties should contact WBB Securities for more information about the report. For more information on WBB Securities, please visit:www.wbbsec.com.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the company's website at http://www.cbiolabs.com.

This press release does not suggest or imply an endorsement by the Company of any projection or recommendation included in any analyst report.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's periodic filings with the Securities and Exchange Commission.

Rachel Levine
Director Corporate Development & Communications
Cleveland BioLabs, Inc.
T: (646) 284-9439
E: rlevine@cbiolabs.com